Cyclo Therapeutics, Inc. (CYTH)
Chart Events
Performance Outlook
| Previous Close | 2.0000 |
| Open | 1.9900 |
| Bid | 2.0000 x 900 |
| Ask | 2.2400 x 3000 |
| Day's Range | 1.9300 - 2.0900 |
| 52 Week Range | 1.8800 - 10.0800 |
| Volume | |
| Avg. Volume | 23,600 |
| Market Cap | 17.001M |
| Beta (5Y Monthly) | -0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8240 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYTH
Related Research
- Cyclo Therapeutics, Inc.Daily – Vickers Top Insider Picks for 03/10/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat4 months agoArgus Research
- Business Wire
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla., June 21, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022.
- Business Wire
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla., May 18, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
- Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
GAINESVILLE, Fla., May 12, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2022 and provided a business update.
